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Introduction: Epidermal growth factor receptor-tyrosine kinase
inhibitors are used as effective first-line and salvage therapy in the
treatment of advanced non-small cell lung cancer (NSCLC) patients
in East Asia. The objective of this study was to compare the efficacy
of gefitinib and erlotinib in Taiwanese patients with advanced
NSCLC.
Methods: Clinical data of NSCLC patients treated with gefitinib or
erlotinib from January 2004 to December 2008 were collected
retrospectively. Five tertiary referral centers in Taiwan participated
in the study.
Results: Of the 1122 patients enrolled, 506 (45%) were female, 594
(53%) were never smokers or former light smokers, and 867 (77%)
were diagnosed with adenocarcinoma. Epidermal growth factor recep-
tor-tyrosine kinase inhibitors were prescribed as first-line treatment in
465 (41%) patients and as second-line or salvage therapy in 657 patients
(59%). The objective response rate was similar between the gefitinib
and erlotinib treatment groups, while disease control rate was 58.9 and
65.8% (p  0.025), respectively. Median progression-free survival of
gefitinib and erlotinib groups was 3.6 and 4.6 months, respectively (p
0.027). Median overall survival of gefitinib and erlotinib groups was 9.6
and 10.7 months, respectively (p  0.013).
Conclusion: Taiwanese patients with advanced NSCLC treated with
erlotinib reported higher disease control rate, longer progression-
free survival, and overall survival compared with patients treated
with gefitinib.
Key Words: Epidermal growth factor receptor, Tyrosine kinase
inhibitors, Non-small cell lung cancer.
(J Thorac Oncol. 2011;6: 148–155)
Worldwide, lung cancer is the leading cause of cancermortality.1 Non-small cell lung cancer (NSCLC) accounts
for the majority of lung cancer cases and is generally diagnosed
at an advanced stage (stage IIIB and IV). Although platinum-
based combination chemotherapy remains the first-line treat-
ment of choice, median survival with these regimens is only 8 to
10 months.2 Second-line chemotherapy, such as docetaxel or
pemetrexed, has a modest but significant effect on symptom
control and survival.3 Major progress in understanding cancer
biology and mechanisms of oncogenesis during the last decade
resulted in the development of molecular targets for NSCLC
treatments. Inhibition of the epidermal growth factor receptor
(EGFR) pathway with tyrosine kinase inhibitors (TKIs) such as
gefitinib and erlotinib provides effective and promising treat-
ment for NSCLC, either first-line or salvage therapy with added
advantage of improved tolerability and quality of life against
chemotherapy agents.4–9 It has been demonstrated that a subset
of patients (females, never smokers, and adenocarcinoma diag-
nosis in patients of East Asian origin) achieved a better response
to TKIs. A higher prevalence of sensitive activating EGFR
mutations (deletion in exon 19 or point mutation of L858R in
exon 21) was found in these individuals.10–12
Gefitinib and erlotinib were each compared with pla-
cebo in phase III randomized trials (ISEL and BR.21, respec-
tively) in which the majority of enrolled patients were Cau-
casian.4,5 Different overall survival outcomes of these two
drugs compared with placebo were widely debated, although
gefitinib demonstrated a significant survival benefit in a
subgroup of patients of Asian origin.6 There are many pos-
sible reasons for this difference in survival. One possible
reason is that the dose intensity or drug concentrations are
higher in patients receiving erlotinib treatment compared with
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gefitinib treatment, because one 150 mg erlotinib tablet is
equal to 2.4 to 2.8 tablets of 250 mg gefitinib (150 mg
erlotinib is equal to 600–700 mg gefitinib).13–16 To our
knowledge, to date, there is no published prospective trial
comparing gefitinib and erlotinib treatment. In this study, we
retrospectively evaluated the difference in efficacy between
these two agents in Taiwanese patients with advanced
NSCLC treated at five institutions. The aim of the study was
to identify clinical predictors to assist physicians in selecting
gefitinib or erlotinib treatment.
PATIENTS AND METHODS
Patients
Between January 2004 and December 2008, patients who
received gefitinib 250 mg daily or erlotinib 150 mg daily with
assessable disease were enrolled into this retrospective study
conducted at five tertiary referral centers in Taiwan. Medical
charts, imaging reports, and images to evaluate treatment re-
sponse were retrospectively reviewed at each center. Clinical
characteristics, including patients’ age, gender, Eastern Cooper-
ative Oncology Group (ECOG) performance status (PS), tumor
cytohistologic type, stage, smoking history, present EGFR-TKI
therapy, body surface area (BSA), best response to prior che-
motherapy, and refractory to prior chemotherapy or not (defined
as recurrent or progressive disease while receiving or within 90
days of last dose of chemotherapy), were recorded.4 Smoking
history was classified as nonsmokers (patients who had smoked
100 cigarettes in their lifetime) or former light smokers (those
who had stopped smoking at least 15 years previously and had
a total of less than 10 pack-years of smoking). The Iressa
Pan-Asia Study population (IPASS population nonsmokers or
former light smokers with adenocarcinoma) was also identified.8
The date of initial diagnosis, date of starting treatment, time to
disease progression, and date of death or last follow-up were
also recorded.
Efficacy Evaluation
Baseline assessments were performed within 3 weeks
before EGFR-TKI treatment. Chest computed tomography
scan (including liver and adrenal glands) was performed
within 3 weeks before starting EGFR-TKI treatment, every 2
to 3 months thereafter, or when confirmation of treatment
response or disease progression was required. Treatment
response evaluation was performed according to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) group
criteria.17 Time to disease progression was calculated from
the date of administration of the first dose of EGFR-TKI to
the date of occurrence of disease progression. Overall sur-
vival was calculated from the starting date of EGFR-TKI to
the date of death. In patients for whom there were no disease
progression at the time of the last follow-up visit, time to
disease progression was censored at the last time point. Date
for patients who were alive was censored as of the date of the
last follow-up visit. This study was approved by the Joint
Institutional Review Board in Taiwan (09-S-014).
Statistical Analysis
All categorical variables were analyzed with 2 tests.
Two-sided t-tests were conducted for continuous variables
when comparing between the two treatment groups. The
objective response rate (complete response  partial re-
sponse) and the disease control rate (complete response 
partial response  stable disease) were compared between
the two treatment groups. Median progression-free survival
and overall survival was estimated by using the Kaplan-Meier
method with log-rank test. Hazard ratios in the overall pop-
ulation and in patient subsets were calculated using the Cox
proportional hazards model. All p values were two sided, and
a value of p  0.05 was considered to be statistically













70 658 449 (62.8) 209 (51.4)
70 464 266 (37.2) 198 (48.6)
Gender 0.001
Male 616 337 (47.1) 279 (68.6)
Female 506 378 (52.9) 128 (31.4)
Smoking history 0.001
Never or light ex-smoker 594 448 (62.7) 146 (35.9)
Other 528 267 (37.3) 261 (64.1)
Performance status NS
0–1 642 413 (57.8) 229 (56.3)
2 480 302 (42.2) 178 (43.7)
Histology 0.001
Adenocarcinoma 867 621 (86.9) 246 (60.4)
Other 255 94 (13.1) 161 (39.6)
Tumor stage NS
IIIB 223 142 (19.9) 91 (22.4)
IV 889 573 (80.1) 316 (77.6)
Received EGFR-TKI as NS
First line 465 309 (43.2) 156 (38.3)
Salvage 657 406 (56.8) 251 (61.7)
IPASS population 0.001
Yes 529 410 (57.3) 119 (29.2)
No 593 305 (42.7) 288 (70.8)
BSAb 0.001
1.64 585 406 (56.8) 179 (44.0)
1.64 537 309 (43.2) 228 (56.0)
Best response to prior
chemotherapyc
NS
CR  PR 121 78 (24.2) 43 (21.5)




Yes 366 207 (64.3) 159 (79.5)
No 156 115 (35.7) 41 (20.5)
a Pearson two-sided 2 test.
b Median body surface area of overall population.
c n 522 (gefitinib 322, erlotinib 200); patients treated with EGFR-TKI as first-line
treatment and those with missing data were excluded.
NS, not significant; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase
inhibitor; BSA, body surface area; CR, complete response; PR, partial response; SD,
stable disease; PD, progressive disease.
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significant. All statistical analyses were performed by using
SPSS software (version 17.0; SPSS Inc., Chicago, IL).
RESULTS
Patients
A total of 1122 patients received EGFR-TKIs treatment
(715 gefitinib, 407 erlotinib). Of these patients, 464 (41.4%)
were aged 70 years or older, 506 (45.1%) were female, 594
(52.9%) were never or former light smokers, 867 patients
(77.3%) were diagnosed with adenocarcinoma, and 529 (47.1%)
met the IPASS population criteria. There were 465 patients
(41.4%) who received EGFR-TKI as first-line treatment, while
the remainder used EGFR-TKI as salvage therapy after failing
previous chemotherapy. More elderly patients, females, never or
former light smokers, and IPASS population received EGFR-
TKIs as first-line treatment, while more patients with PS 2 or
higher received EGFR-TKIs as salvage therapy. Baseline demo-
graphics of the two treatment groups are shown in Table 1.
There were significantly more elderly, males, and smoking
patients with nonadenocarcinoma histology in the erlotinib treat-
ment group. This group also contained significantly more pa-
tients of the non-IPASS population.
TABLE 2. Comparison of Objective Response Rate and Disease Control Rate Between Treatment
Groups








(n  407) pa
Overall 34.4 35.6 NS 58.9 65.8 0.025
Age (yr)
70 35.9 40.2 NS 61.2 66.5 NS
70 31.2 30.8 NS 54.9 65.2 0.033
Gender
Male 23.4 27.6 NS 48.1 59.5 0.006
Female 44.2 53.1 NS 68.5 79.7 0.021
Smoking history
Never or light ex-smoker 44.6 53.4 NS 69.9 78.1 NS
Other 17.2 25.7 0.02 40.5 59.0 0.001
Histology
Adenocarcinoma 38.5 43.9 NS 64.3 72.8 0.02
Other 7.4 23 0.003 23.4 55.3 0.001
ECOG PS
0–1 28.6 33.2 NS 71.4 73.8 NS
2 18.9 31.5 0.002 41.7 55.6 0.004
Stage at diagnosis
IIIB 26.1 25.3 NS 26.1 25.3 NS
IV 36.5 38.6 NS 36.5 38.6 NS
Received EGFR-TKI as
First line 38.4 39.8 NS 59.9 69.9 0.044
Salvage 31.5 33.1 NS 58.1 63.3 NS
IPASS population
Yes 47.3 54.6 NS 73.2 79.8 NS
No 17.1 27.8 0.003 39.7 60.1 0.001
BSAb
1.64 39.2 43.0 NS 61.8 72.1 0.032
1.64 28.2 29.8 NS 55.2 61.0 NS
Best Response to prior chemotherapyc
CR  PR 39.7 30.2 NS 62.8 58.1 NS
SD  PD 26.6 31.8 NS 53.3 61.8 NS
Refractory to prior chemotherapyc
Yes 29.0 32.7 NS 51.2 59.7 NS
No 31.3 26.8 NS 63.5 65.9 NS
a Pearson two-sided 2 test.
b Median body surface area of overall population.
c n 522 (gefitinib 322, erlotinib 200); patients treated with EGFR-TKI as first-line treatment and those with missing data were excluded.
NS, not significant; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; ECOG PS, Eastern Cooperative Oncology
Group performance status; IPASS, Iressa Pan-Asia Study; BSA, body surface area; CR, complete response; PR, partial response; SD, stable
disease; PD, progressive disease.
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The majority of female patients were nonsmokers, and
the majority of male patients were smokers. Male patients
had larger BSA compared with female patients (median, 1.71
versus 1.55 m2, p  0.001). BSA in the erlotinib group was
larger than the BSA in the gefitinib group (median, 1.67
versus 1.62 m2, p  0.001). PS, tumor stage, line of TKI
treatment, and best response to prior chemotherapy were
balanced between the two treatment groups.
Treatment Response
Objective response rate to EGFR-TKI was similar be-
tween gefitinib and erlotinib treatment groups (34.4 versus
35.6%, p  0.728; Table 2). Erlotinib was statistically supe-
rior to gefitinib in terms of disease control rate (58.9 versus
65.8%, p  0.025; Table 2). When analyzing subgroups of
patients, the response rate was statistically higher with erlo-
tinib treatment in current or former nonlight smokers, patients
with nonadenocarcinoma, poor PS (ECOG PS 2), and
patients from the non-IPASS population (Table 2). Disease
control rate was statistically greater with erlotinib treatment
in both male and female elderly patients, current or former
nonlight smokers, regardless of histology type, PS 2, BSA
1.64, and non-IPASS population (Table 2).
Progression-Free Survival
Progression-free survival was longer in the erlotinib
group compared with the gefitinib group (median, 4.6 versus
3.6 months; hazard ratio: 0.87; 95% confidence interval [CI]:
0.76–0.98; p  0.027) in the entire study population based
on the unadjusted analysis (Figure 1). Similar results were
obtained from supportive Cox regression analysis adjusted
for covariates, including gender, performance status, IPASS
or non-IPASS population, and BSA. Among the patients’
characteristics, performance status of 2 or higher and non-
IPASS population coincide with shorter progression-free sur-
vival than their contraries, independent of which TKI was
used (Table 3). On the other hand, progression-free survival
was not influenced by the patient’s age, gender, tumor stage,
line of TKI treatment, and BSA. Noteworthy, erlotinib
reached longer progression-free survival in both IPASS (me-
dian, 7.2 versus 5.1 months; p  0.001) and non-IPASS
populations (3.6 versus 2.0 months; p  0.002) (Figure 2).
Overall Survival
Overall survival was longer in the erlotinib group
compared with the gefitinib group (median, 10.7 versus 9.6
months; hazard ratio: 0.84; 95% CI: 0.73–0.96; p 0.013) in
the entire study population based on the unadjusted analysis
(Figure 3). Similar results were obtained from supportive Cox
regression analysis adjusted for covariates, including gender,
performance status, IPASS or non-IPASS population, and
line of TKI treatment. Among the patients’ characteristics, PS
of 2 or higher and non-IPASS population coincide with
FIGURE 1. Kaplan-Meier analysis of progression-free sur-
vival after the start of EGFR-TKIs. Erlotinib treatment was as-
sociated with a longer progression-free survival compared
with gefitinib treatment (median, 4.6 versus 3.6 months,
p  0.027).










HR Pa HR Pb
Treatment group 1.151 0.027 1.265 0.016
Gefitinib (n  715) 3.6
Erlotinib (n  497) 4.6
Age 1.012 0.702
70 yr (n  464) 3.5
70 yr (n  658) 4.4
Gender 1.163 0.001 1.232 0.113
Male (n  616) 2.8
Female (n  506) 5.1
Performance status
(ECOG)
0.729 0.001 0.489 0.001
0–1 (n  642) 5.4
2 (n  480) 2.1
IPASS population 0.792 0.001 0.725 0.009
Yes (n  529) 5.5
No (n  593) 2.3
Tumor stage 1.046 0.237
IIIB (n  233) 3.1
IV (n  889) 4.4
Received TKI as 0.956 0.741
First line (n  465) 4.3
Salvage (n  657) 3.8
BSAc 0.934 0.025 0.912 0.361
1.64 (n  585) 4.6
1.64 (n  537) 3.5
a Kaplan-Meier analysis by log-rank test.
b Cox regression.
c Median body surface area of overall population.
ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; TKI, tyrosine
kinase inhibitor; PFS, progression-free survival; BSA, body surface area; IPASS, Iressa
Pan-Asia Study.
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shorter overall survival than their contraries, independent of
which TKI was used (Table 4). On the other hand, overall
survival was not influenced by the patient’s age, gender,
tumor stage, line of TKI treatment, and BSA.
The timing of two agents became commercially avail-
able in Taiwan was different, gefitinib in August 2003 and
erlotinib in March 2006. To eliminate the potential effects of
the difference in its availability, patients (N  816) who
started EGFR-TKIs treatment after March 2006, when the
both agents were commercially available in Taiwan, were
analyzed. There were significantly more patients with unfa-
vorable clinical predictors for EGFR-TKI response (males,
smokers, and nonadenocarcinoma histology) in the erlotinib
treatment group. Consistent with the overall population, er-
lotinib (N  376) reached longer progression-free survival
and overall survival than gefitinib (N  440). Median pro-
gression-free survival of gefitinib and erlotinib groups were
4.0 and 4.9 months, respectively (p  0.035). Median overall
survival of gefitinib and erlotinib groups were 10.0 and 11.1
months, respectively (p  0.034).
IPASS or Non-IPASS Population
In the IPASS population (clinical-enriched tumor
EGFR exon 19 or 21 mutated patients), there was no signif-
icant difference between the two treatments in terms of
response rate and disease control rate, irrespective of gender
or BSA groups. Progression-free survival was longer with
erlotinib compared with gefitinib in females and both BSA
groups of the IPASS population (Table 5). In the non-IPASS
population, disease control rate was statistically higher and
progression-free survival was longer with erlotinib than with
gefitinib irrespective of gender or BSA groups. In females
and patients in the lower BSA group, the response rate was
statistically higher with erlotinib (Table 5).
DISCUSSION
Treatment with one of the EGFR-TKIs, gefitinib or
erlotinib, has become an important option for patients with
advanced NSCLC, especially in Asian patients. The tumor
EGFR mutation rate is about three times more prevalent in
FIGURE 2. Kaplan-Meier analysis of progression-free survival after the start of EGFR-TKIs in IPASS population (A) and non-
IPASS population (B). Erlotinib treatment resulted in longer progression-free survival in both the IPASS (median, 7.2 versus 5.1
months, p  0.001) and non-IPASS populations (median, 3.6 versus 2 months, p  0.002).
FIGURE 3. Kaplan-Meier analysis of overall survival after the
start of EGFR-TKIs. Erlotinib treatment was associated with a
longer overall survival compared with gefitinib treatment
(median, 10.7 versus 9.6 months, p  0.013).
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Asian patients than Caucasians. An effect on overall survival
in genotypically uncharacterized NSCLC patients was ob-
served with erlotinib (BR.21 trial),5 but not gefitinib (ISEL
trial),4 although the response rates were similar. Several
possible explanations were discussed, including the refrac-
tory, difficult-to-treat nature of the population in the ISEL
study, and suboptimal dosing of gefitinib. Erlotinib was used
at its maximum tolerated dose (MTD), whereas gefitinib was
used at approximately one-third of its MTD.13–16 The stan-
dard doses of erlotinib and gefitinib are not biologically
equivalent. Erlotinib treatment may be more efficacious than
gefitinib in wild-type EGFR lung tumors because erlotinib
inhibits the activity of wild-type EGFR-TKI in tumor cells at
50% inhibitory concentration of 2 to 20 nmol/L. In contrast,
for gefitinib to block wild-type EGFR signaling, several-fold
higher drug concentrations are required.18–21 This result was
supported by evidence from patients lacking EGFR mutations
who still achieved a benefit from erlotinib after failure of
gefitinib treatment.22 In addition, the survival impact of
erlotinib was not confounded significantly by tumor cell
EGFR mutation status in a recent molecular analysis of the
BR.21 trial.23 Furthermore, the SATURN trial that tested
maintenance erlotinib after chemotherapy showed that pro-
gression-free survival and overall survival were prolonged in
patients with or without an EGFR mutation.24 These results
indicate that erlotinib therapy is beneficial irrespective of
EGFR mutation status. Our results consistently showed better
response rate, disease control rate, and longer progression-
free survival in current or former nonlight smokers, nonade-
nocarcinoma histology, and non-IPASS population patients
(Table 5). These patients are considered less likely to harbor
sensitive activating EGFR mutations.
In our study, more patients with unfavorable clinical
predictors for EGFR-TKI response received erlotinib treat-
ment. The most likely reasons were physicians’ preference
and in Taiwan, the National Health Insurance policy allowed
patients with nonadenocarcinoma histology to receive only




ORR (%) DCR (%) Median PFS (Months)
G E pa G E pa G E pb
Male (G 83, E 30) 39.8 50 NS 72.3 73.3 NS 5.1 7.2 0.09
Female (G 327, E 89) 49.2 56.2 NS 73.4 82 NS 5.2 7.3 0.002
BSA
1.58c (G 221, E 59) 52.5 61 NS 75.1 86.4 NS 5.6 7.3 0.009
1.58 (G 189, E 60) 41.3 48.3 NS 70.9 73.3 NS 5 7.2 0.009
Non-IPASS Population 593 G E p G E p G E p
Male (G 254, E 249) 18.1 24.9 0.08 40.2 57.8 0.001 2 3 0.021
Female (G 51, E 39) 11.8 46.2 0.001 37.3 74.4 0.001 1.9 5 0.007
BSA
1.68d (G 162, E 128) 16.5 28.9 0.003 34.6 58.6 0.001 2 3.5 0.017
1.68 (G 143, E 160) 20.3 26.9 0.226 45.5 61.3 0.008 2 3.6 0.052
a 2 test.
b Log-rank test.
c Median BSA of IPASS population.
d Median BSA of non-IPASS population.
ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; G, gefitinib; E, erlotinib; BSA, body surface area; IPASS, Iressa Pan-Asia Study.









HR Pa HR Pb
Treatment group 1.196 0.013 1.477 0.001
Gefitinib (n  715) 9.6
Erlotinib (n  497) 10.7
Age 1.127 0.075
70 yr (n  464) 9.2
70 yr (n  658) 10.5
Gender 1.388 0.001 1.064 0.468
Male (n  616) 8.0
Female (n  506) 12.2
Performance status
(ECOG)
0.397 0.001 0.396 0.001
0–1 (n  642) 13.4
2 (n  480) 5.4
IPASS population 0.626 0.001 0.626 0.001
Yes (n  529) 12.6
No (n  593) 7.3
Tumor stage 0.980 0.810
IIIB (n  233) 10.5
IV (n  889) 9.9
Received TKI as 0.841 0.010 0.994 0.928
First line (n  465) 11.5
Salvage (n  657) 9.1
BSAc 0.974 0.690
1.64 (n  585) 10.3
1.64 (n  537) 9.6
a Kaplan-Meier analysis by log-rank test.
b Cox regression.
c Median body surface area of overall population.
ECOG, Eastern Cooperative Oncology Group; OS, overall survival; HR, hazard
ratio; TKI, tyrosine kinase inhibitor; PFS, progression-free survival; IPASS, Iressa
Pan-Asia Study.
Journal of Thoracic Oncology • Volume 6, Number 1, January 2011 Erlotinib and Gefitinib in Advanced NSCLC Patients
Copyright © 2010 by the International Association for the Study of Lung Cancer 153
erlotinib reimbursement as salvage EGFR-TKI treatment.
Therefore, more patients who were refractory to prior che-
motherapy subsequently received erlotinib treatment.
The higher clinical benefits with erlotinib observed in
patients with lower BSA and female patients of the non-
IPASS population (Table 5) may be due to the relative higher
dose intensity of erlotinib compared with gefitinib. The issue
of dose intensity as reflected in the differences observed in
serum concentrations of erlotinib and gefitinib cannot be
overemphasized. The antitumor effects in the central nervous
system (CNS) may be different between the two drugs be-
cause of incomplete CNS penetration hindered by the blood-
brain barrier. Treatment with erlotinib or using an increased
dose of gefitinib is proven to be a reasonable strategy to
circumvent the EGFR-TKI-sensitive tumor cells that are
present in the CNS.25–27 Based on these results, erlotinib may
confer better CNS control compared with gefitinib because of
its MTD design.
EGFR mutation pattern rather than mutation status may
have implications for the selection of specific EGFR
TKI.28–30 Moreover, it is not known if both drugs are equally
active for the most common, classic mutations (in-frame
deletions of exon 19 and missence point mutation in exon 21
leading to L858R). The deletion in exon 19 exhibits malig-
nant transforming abilities compared with the exon 21 point
mutation (L858R), and this difference may reflect patient
survival.31,32 In a recent Spanish study, patients with exon 19
deletions had a longer PFS and overall survival compared
with those carrying L858R mutations when treated with
erlotinib.9 In contrast, recent Japanese trials did not detect any
difference.33,34 On the other hand, Paz-Ares et al. reported a
pooled analysis of published studies that evaluated clinical
outcomes in patients with EGFR-mutated NSCLC who were
treated with chemotherapy or EGFR-TKIs. The results
showed that the overall median progression-free survival was
13.2 months with erlotinib, 9.8 months with gefitinib, and 5.9
months with chemotherapy.35
Lack of tumor EGFR genotype analysis of our patients
may be a limitation of concern. Accurate EGFR genotype
analysis of patient groups included in this study would assist
to elucidate the true difference between these two similar
EGFR-TKIs. The IPASS study confirmed that clinical-en-
riched patients were approximately 60% EGFR mutation
positive.36 Accordingly, we divided our patients into IPASS
or non-IPASS population to clarify the efficacy relationship
between these two EGFR-TKIs.
The study has several other limitations. First, this is a
retrospective study with inherent potential for bias. Second,
toxicity profiles are not reported in this study. It was consid-
ered that there may be some differences in the frequency of
adverse effects between the two agents because of different
dose intensity. Third, use of these two drugs was affected by
the National Health Insurance policy in Taiwan. Physicians’
preference may also be considered as limitation of the study.
Although more patients in the erlotinib group exhibited non-
favorable clinical characteristics for EGFR-TKI use, similar
response rates and improved disease control rates were
achieved compared with the gefitinib group.
In conclusion, erlotinib reached better disease control
rates, longer progression-free survival, and overall survival
than gefitinib in Taiwanese patients with advanced NSCLC.
It is reasonable to use erlotinib in patients with unknown
EGFR mutation status to achieve higher dose intensity unless
unacceptable toxicities occurred. Further prospective ran-
domized trials based on tumor EGFR genotype to compare
gefitinib and erlotinib are needed.
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